Gefapixant in two randomised dose-escalation studies in chronic cough
Jaclyn A. Smith, Michael M. Kitt, Peter Butera, Steven A. Smith, Yuping Li, Zhi Jin Xu, Kimberley Holt, Shilpi Sen, Mandel R. Sher, Anthony P. Ford
European Respiratory Journal 2020 55: 1901615; DOI: 10.1183/13993003.01615-2019
Jaclyn A. Smith
1University of Manchester and Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK
Michael M. Kitt
2Merck & Co., Inc., Kenilworth, NJ, USA
Peter Butera
2Merck & Co., Inc., Kenilworth, NJ, USA
Steven A. Smith
2Merck & Co., Inc., Kenilworth, NJ, USA
Yuping Li
3GetStat Solutions, LLC, Palo Alto, CA, USA
Zhi Jin Xu
2Merck & Co., Inc., Kenilworth, NJ, USA
Kimberley Holt
1University of Manchester and Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK
Shilpi Sen
1University of Manchester and Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK
Mandel R. Sher
4Center for Cough, Largo, FL, USA
Anthony P. Ford
2Merck & Co., Inc., Kenilworth, NJ, USA
Vol 55 Issue 3
Table of Contents
Gefapixant in two randomised dose-escalation studies in chronic cough
Jaclyn A. Smith, Michael M. Kitt, Peter Butera, Steven A. Smith, Yuping Li, Zhi Jin Xu, Kimberley Holt, Shilpi Sen, Mandel R. Sher, Anthony P. Ford
European Respiratory Journal Mar 2020, 55 (3) 1901615; DOI: 10.1183/13993003.01615-2019
Gefapixant in two randomised dose-escalation studies in chronic cough
Jaclyn A. Smith, Michael M. Kitt, Peter Butera, Steven A. Smith, Yuping Li, Zhi Jin Xu, Kimberley Holt, Shilpi Sen, Mandel R. Sher, Anthony P. Ford
European Respiratory Journal Mar 2020, 55 (3) 1901615; DOI: 10.1183/13993003.01615-2019